US Pharma MarketingAlumis falls after TYK2 pill fails lupus study, but CEO sees
Alumis Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation power FDA policy and drug approvals: What’s changing…
Alumis' lead drug program suffered a clinical setback Tuesday as the San Francisco biotech reported its TYK2 pill failed a mid-stage lupus study.
The results put a damper on what has ...
Source: Endpoints News